← Back to Clinical Trials
Recruiting NCT07666347

NCT07666347 Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07666347
Status Recruiting
Phase
Sponsor Tanta University
Condition Intraarticular Injection
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-06-24
Primary Completion 2026-12-01

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Hyaluronic acidBotulinum toxin type A

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-06-24 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 50 years. * Both genders. * Chronic knee osteoarthritis (KOA) according to American College of Rheumatology criteria for the diagnosis of knee osteoarthritis. * Third or fourth grade Kellgren and Lawrence system for classification of osteoarthritis based on radiological data, it is a common method of classifying the severity of osteoarthritis (OA) using five grades according to the following sites and projections. Exclusion Criteria: * History of intra-articular injection within the last 6 months, * History of surgery on the knee joint or major trauma to the lower limb causing fracture. * Body mass index (BMI) more than 40 kg/m2. * Medical conditions affecting the joint or lower extremity function such as severe osteoporosis, rheumatoid arthritis, collagen vascular diseases, and gout. * Diabetic patient. * Any contraindication to intra-articular injections for instance immunodeficiency, coagulation defect or anticoagulation therapy taking or skin infection at the site of injection. * Hypersensitivity to Botulinum toxin or hyaluronic acid.

Contact & Investigator

Central Contact

Mohammed S ElSharkawy, MD

✉ mselsharkawy@med.tanta.edu.eg

📞 00201148207870

Frequently Asked Questions

Who can join the NCT07666347 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Intraarticular Injection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07666347 currently recruiting?

Yes, NCT07666347 is actively recruiting participants. Contact the research team at mselsharkawy@med.tanta.edu.eg for enrollment information.

Where is the NCT07666347 trial being conducted?

This trial is being conducted at Tanta, Egypt.

Who is sponsoring the NCT07666347 clinical trial?

NCT07666347 is sponsored by Tanta University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology